Global Information
회사소개 | 문의 | 비교리스트

세계의 중추신경계 장애용 유전자 치료 시장(2019-2023년)

Global Gene Therapy for CNS Disorders Market 2019-2023

리서치사 TechNavio (Infiniti Research Ltd.)
발행일 2019년 03월 상품 코드 823144
페이지 정보 영문 119 Pages
가격
US $ 2,500 ₩ 3,098,000 PDF by E-mail (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 3,000 ₩ 3,718,000 PDF by E-mail (5-user License) help
동일 사업장 내 5명까지 공유하여 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,957,000 PDF by E-mail (Enterprise License) help
동일 기업 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 5,000 ₩ 6,197,000 PDF by E-mail (Global License) help
동일 기업 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다. 또한 해당 라이선스는 보고서 컨텐츠의 15% 이내로 외부용 문서에 인용 게재가 허용됩니다(예:프레스릴리스, 마케팅 자료, 백서 등).


세계의 중추신경계 장애용 유전자 치료 시장(2019-2023년) Global Gene Therapy for CNS Disorders Market 2019-2023
발행일 : 2019년 03월 페이지 정보 : 영문 119 Pages

특별 약제의 지정 증가는 향후 수년간 시장이 지속적으로 성장하기 위한 주요 요소 중 하나로 전망됩니다. 신속한 승인을 지원하기 위해 벤더는 신규 유전자 치료를 위한 특별 약물 지정을 받고 있습니다. 일부 시장 관계자는 임상 연구에 다양한 세제 혜택이 포함된 희귀의약품 지정도 제공하고 있습니다. 그 결과, 규제기관으로부터의 특별 약물 지정 증가에 의해 향후 수년간 CNS 장애용 유전자 치료(Gene Therapy for CNS Disorders) 시장의 성장이 촉진될 전망입니다. Technavio의 애널리스트는 세계의 CNS 장애용 유전자 치료 시장이 2023년까지 약 27%의 CAGR로 성장할 것으로 예측했습니다.

세계의 중추신경계 장애용 유전자 치료 시장에 대해 조사분석했으며, 시장 규모와 성장률, 시장 동향, 시장 성장 촉진요인·과제, 시장 기회 검증 및 주요 벤더 등에 관한 정보를 정리하여 전해드립니다.

제1장 개요

제2장 리포트의 범위

  • 서론 1
  • 서론 2
  • 달러의 통화 환산율

제3장 시장 상황

  • 시장 에코시스템
  • 시장의 특징
  • 시장 세분화 분석

제4장 시장 규모

  • 시장의 정의
  • 시장 규모(2018년)
  • 시장 규모 및 예측(2018-2023년)

제5장 Five Forces 분석

  • 바이어의 교섭력
  • 공급업체의 교섭력
  • 신규 진출의 위협
  • 대체품의 위협
  • 경쟁 상대의 위협
  • 시장 현황

제6장 파이프라인

제7장 시장 세분화 : 증상별

  • 시장 세분화 : 증상별
  • 증상별 비교 : 시장 규모 및 예측(2018-2023년)
  • SMA
  • 기타
  • 시장 기회 : 증상별

제8장 고객 상황

제9장 지역 상황

  • 지역별 세분화
  • 지역별 비교 : 시장 규모 및 예측(2018-2023년)
  • 북미
  • 유럽
  • 아시아
  • 기타 지역
  • 주요 국가
  • 시장 기회

제10장 의사결정 프레임워크

제11장 성장요인과 과제

  • 시장 성장요인
  • 시장이 해결해야 할 과제

제12장 시장 동향

제13장 벤더 구도

  • 개요
  • 창조적 파괴 상황
  • 경쟁 시나리오

제14장 벤더 분석

  • 대상 벤더
  • 벤더 분류
  • 벤더의 시장 포지셔닝
  • Biogen
  • bluebird bio, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Voyager Therapeutics

제15장 부록

  • 조사 방법
  • 약어 리스트

제16장 TECHNAVIO 소개

KSA 19.04.19

About this market

The increase in special drug designations is one of the key factors anticipated to witness continuous growth in the forthcoming years. Vendors are receiving special drug designations for their novel gene therapies to help in receiving quicker approval. Some market players are even offering the orphan drug designation with various tax benefits on their clinical researches. As a result, the rising number of special drug designations from the regulatory bodies will drive the gene therapy for CNS disorders market growth in the forthcoming years. Technavio's analysts have predicted that the gene therapy for CNS disorders market will register a CAGR of nearly 27% by 2023.

Market Overview

Increase in special drug designations

One of the growth drivers of the global gene therapy for CNS disorders market is the increase in special drug designations. The increasing number of special drug designations from the regulatory bodies is expected to result in the quicker approval of gene therapy programs, which drives the growth of the market.

Uneven distribution of technology

One of the challenges in the growth of the global gene therapy for CNS disorders market is the Uneven distribution of technology. The lack of focus of major vendors on developing gene therapy for CNS disorders are expected to hinder the market growth during the forecast period.

For the detailed list of factors that will drive and challenge the growth of the gene therapy for CNS disorders market during 019-2023, view our report.

Competitive Landscape

The market appears to be highly concentrated with the presence of a few market players. Vendors in the market are developing advanced technologies that help in manufacturing gene therapies with superior efficacy for the treatment of various CNS indications. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: PIPELINE

PART 07: MARKET SEGMENTATION BY INDICATION

  • Market segmentation by indication
  • Comparison by indication
  • SMA - Market size and forecast 2018-2023
  • Others - Market size and forecast 2018-2023
  • Market opportunity by indication

PART 08: CUSTOMER LANDSCAPE

PART 09: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 10: DECISION FRAMEWORK

PART 11: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 12: MARKET TRENDS

PART 13: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 14: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Biogen
  • bluebird bio, Inc.
  • Novartis AG
  • Pfizer Inc.
  • Voyager Therapeutics

PART 15: APPENDIX

  • Research methodology
  • List of abbreviations

PART 16: EXPLORE TECHNAVIO

List of Exhibits

  • Exhibit 01: Global pharmaceuticals market
  • Exhibit 02: Segments of global pharmaceuticals market
  • Exhibit 03: Market characteristics
  • Exhibit 04: Market segments
  • Exhibit 05: Market definition - Inclusions and exclusions checklist
  • Exhibit 06: Market size 2018
  • Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 09: Five forces analysis 2018
  • Exhibit 10: Five forces analysis 2023
  • Exhibit 11: Bargaining power of buyers
  • Exhibit 12: Bargaining power of suppliers
  • Exhibit 13: Threat of new entrants
  • Exhibit 14: Threat of substitutes
  • Exhibit 15: Threat of rivalry
  • Exhibit 16: Market condition - Five forces 2018
  • Exhibit 17: Global gene therapy for CNS disorders market pipeline: Overview
  • Exhibit 18: Global gene therapy for CNS disorders market pipeline: Snapshot
  • Exhibit 19: Indication - Market share 2018-2023 (%)
  • Exhibit 20: Comparison by indication
  • Exhibit 21: SMA - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 22: SMA - Year-over-year growth 2019-2023 (%)
  • Exhibit 23: Others - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 24: Others - Year-over-year growth 2019-2023 (%)
  • Exhibit 25: Market opportunity by indication
  • Exhibit 26: Customer landscape
  • Exhibit 27: Market share by geography 2018-2023 (%)
  • Exhibit 28: Geographic comparison
  • Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 30: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 31: Top 3 countries in North America
  • Exhibit 32: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 33: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 34: Top 3 countries in Europe
  • Exhibit 35: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 36: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 37: Top 3 countries in Asia
  • Exhibit 38: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 39: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 40: Top 3 countries in ROW
  • Exhibit 41: Key leading countries
  • Exhibit 42: Market opportunity
  • Exhibit 43: Impact of drivers and challenges
  • Exhibit 44: Vendor landscape
  • Exhibit 45: Landscape disruption
  • Exhibit 46: Vendors covered
  • Exhibit 47: Vendor classification
  • Exhibit 48: Market positioning of vendors
  • Exhibit 49: Biogen - Vendor overview
  • Exhibit 50: Biogen - Business segments
  • Exhibit 51: Biogen - Organizational developments
  • Exhibit 52: Biogen - Geographic focus
  • Exhibit 53: Biogen - Key offerings
  • Exhibit 54: Biogen - Key customers
  • Exhibit 55: bluebird bio, Inc. - Vendor overview
  • Exhibit 56: bluebird bio, Inc. - Product segments
  • Exhibit 57: bluebird bio, Inc. - Organizational developments
  • Exhibit 58: bluebird bio, Inc. - Key offerings
  • Exhibit 59: bluebird bio, Inc. - Key customers
  • Exhibit 60: Novartis AG - Vendor overview
  • Exhibit 61: Novartis AG - Business segments
  • Exhibit 62: Novartis AG - Organizational developments
  • Exhibit 63: Novartis AG - Geographic focus
  • Exhibit 64: Novartis AG - Segment focus
  • Exhibit 65: Novartis AG - Key offerings
  • Exhibit 66: Novartis AG - Key customers
  • Exhibit 67: Pfizer Inc. - Vendor overview
  • Exhibit 68: Pfizer Inc. - Business segments
  • Exhibit 69: Pfizer Inc. - Organizational developments
  • Exhibit 70: Pfizer Inc. - Geographic focus
  • Exhibit 71: Pfizer Inc. - Segment focus
  • Exhibit 72: Pfizer Inc. - Key offerings
  • Exhibit 73: Pfizer Inc. - Key customers
  • Exhibit 74: Voyager Therapeutics - Vendor overview
  • Exhibit 75: Voyager Therapeutics - Business segments
  • Exhibit 76: Voyager Therapeutics - Organizational developments
  • Exhibit 77: Voyager Therapeutics - Key offerings
  • Exhibit 78: Voyager Therapeutics - Key customers
  • Exhibit 79: Validation techniques employed for market sizing
Back to Top
전화 문의
F A Q